UAS-RBS: a Safety Study

Refractory Benign Strictures Clinical Trial

Official title:

Universal Partially Covered Removable Self-Expanding Stent and Anchoring System for the Treatment of Refractory Benign Esophageal Strictures (UAS-RBS): a Safety Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03652285
• Other study ID #: P2017/543
• Status: Completed
• Phase: N/A
• Start date: March 27, 2018
• Est. completion date: March 31, 2021

Study information

• Verified date: February 2022
• Source: Erasme University Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A novel stent, called Universal Partially Covered Removable Self-expanding Stent and Anchoring System for the Treatment of Refractory Benign Esophageal Strictures (UAS-RBS) was designed to improve the treatment of benign esophageal refractory strictures with a novel stent. This study aims at evaluating the safety of this new device.

Description:

Refractory strictures are defined as benign esophageal strictures who do not achieve acceptable symptom relief despite an intensive dilation schedule. Considering the failure of balloon or mechanical dilation other techniques such as intralesional injection of corticosteroids or stents placement were developed.

Self-expandable metal stents, plastic stents and biodegradable stents are also used in that indication. In a meta-analysis of 18 studies with 444 patients, clinical success was achieved in 41 percent of patients. Stent migration occurred in 29 percent of patients, and adverse events occurred in 21 percent.

A self-expending nitinol stent has been design to reduce the migration risk. The stent is partially covered on both extremities, allowing the formation of small hyperplasia in the middle part of the stent. This design with the inner sheet (usually, when using fully covered stents, the sheet is outside) allows formation of hyperplasia (therefore reducing the risk of migration) but partly controlled by the inner sheet to reduce the risk of lumen occlusion. By this design, the balance between hyperplasia formation to avoid the risk of migration and reducing the risk of lumen occlusion could be entailed stable esophageal calibration.

The UAS-RBS system is a reversible procedure to treat Refractory Benign Esophageal Strictures through stent implantation. Above standard of care monitoring, safety assessment of the procedure and device performance decreases the risk and unforeseen events.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 11
• Est. completion date: March 31, 2021
• Est. primary completion date: March 31, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Benign Esophageal Refractory Stricture no more than 40 mm in length.

• More than two dilations to at least 16 mm in diameter with symptoms relapse within 6 months.

• Last dilation to 16 mm no more than 6 months before study procedure.

• Dysphagia score of 2 (ability to swallow semi-solid foods), 3 (ability to swallow liquids only) or 4 (unable to swallow liquids) at the time of measurement.

• Willing and able to comply with the study procedures and provide written informed consent to participate in the study.

Exclusion Criteria:

• Stricture within 2 cm of the upper esophageal sphincter.

• Dysphagia related to motility disorder.

• Planned adjuvant radiation therapy post esophagectomy.

• Esophageal stent in place.

• Active erosive esophagitis.

• Sensitivity to any components of the stent or delivery system.

• Concurrent medical condition that would affect the investigator's ability to evaluate the patient's condition or could compromise patient safety.

• Currently enrolled in another clinical trial.

Related Conditions & MeSH terms

• Constriction, Pathologic
• Refractory Benign Strictures

Intervention

Device:
• Esophageal stent implantation
An upper endoscopy will be performed with the use of fluoroscopy. Depending on the size of the stricture a dilation can be performed prior to the stent deployment. Otherwise, the stent will be deployed over a guidewire, under fluoroscopy. After, the gastroscopy will go through the esophagus to check for the stent deployment, or any complications. An injection of contrast agent will be done to be sure of the correct positioning and that no complications was happened. The patient will be kept overnight, with liquid food for 3 days and under PPI until one month after the stent placement.
• Stent removal
Six months after implantation, the removal of the stent will be performed. Patient will undergo a first endoscopy under general anesthesia for the placement of a FCSEMS. Then, depending on the importance of the hyperplasia, removal of both stents, under general anesthesia, will be done after 7 to 10 days.

Locations

Country	Name	City	State
Belgium	CUB Hopital erasme	Anderlecht

Sponsors (1)

Lead Sponsor	Collaborator
Erasme University Hospital

Country where clinical trial is conducted

Belgium, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of all Adverse Device Effects	Serious adverse event (SAE) during the period of stent implantation	6 months
Primary	Technical stent placement success	Ability to deploy the UAS-RBS in satisfactory position across the stricture	Day 0
Primary	Full deployment of stent	Endoscopic visualization	Day 0
Primary	Technical stent removal success	Ability to remove the stent without complications	up to 6 months
Secondary	SAE during the period after stent removal		6 months post retrieval
Secondary	Number of re-interventions		within 12 months following stent placement
Secondary	Change of dysphagia score (Dakkak and Bennett score of Dysphagia)		Baseline and at week 1, month 1, 2, 3, 6, 9, 12 after implantation
Secondary	Patient's satisfaction with the therapy	scored by a visual analog scale (0 worse - 10 best)	week 1, month 1, 2, 3, 6, 9, 12 after implantation
Secondary	Patient's report of pain	scored by a visual analog scale (0 worse - 10 best)	before treatment, and at week 1, month 1, 2, 3, 6, 9, 12 after implantation
Secondary	Quality Of Life SF36 questionnaire	SF36	before treatment, and at week 1, month 1, 2, 3, 6, 9, 12 after implantation